Brian Schillinger

469 total citations
10 papers, 373 citations indexed

About

Brian Schillinger is a scholar working on Oncology, Cancer Research and Epidemiology. According to data from OpenAlex, Brian Schillinger has authored 10 papers receiving a total of 373 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Cancer Research and 3 papers in Epidemiology. Recurrent topics in Brian Schillinger's work include Pancreatic and Hepatic Oncology Research (9 papers), Cancer Genomics and Diagnostics (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Brian Schillinger is often cited by papers focused on Pancreatic and Hepatic Oncology Research (9 papers), Cancer Genomics and Diagnostics (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Brian Schillinger collaborates with scholars based in United States. Brian Schillinger's co-authors include Alan P. Venook, Andrew H. Ko, Emily K. Bergsland, Margaret A. Tempero, Elizabeth Dito, Janet H. Scott, Jimmy J. Hwang, Jeanne M. Quivey, W. Michael Korn and Robin Kate Kelley and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Cancer Chemotherapy and Pharmacology.

In The Last Decade

Brian Schillinger

10 papers receiving 362 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brian Schillinger United States	7	317	116	98	91	85	10	373
Aiwen Wu China	11	283 0.9×	83 0.7×	124 1.3×	98 1.1×	99 1.2×	29	429
Francesca Sparano Italy	9	219 0.7×	65 0.6×	103 1.1×	113 1.2×	78 0.9×	19	369
Anna‐Kaisa Eerola Finland	6	264 0.8×	60 0.5×	66 0.7×	182 2.0×	125 1.5×	7	407
T Ichihara Japan	11	179 0.6×	79 0.7×	75 0.8×	119 1.3×	28 0.3×	23	353
Lee B. Riley United States	9	238 0.8×	108 0.9×	67 0.7×	91 1.0×	25 0.3×	14	366
Marion Jacquin France	8	161 0.5×	68 0.6×	56 0.6×	156 1.7×	128 1.5×	16	340
Zuoxing Niu China	9	152 0.5×	112 1.0×	103 1.1×	163 1.8×	56 0.7×	40	376
Eriko Yokoi Japan	16	329 1.0×	101 0.9×	47 0.5×	104 1.1×	258 3.0×	24	588
Simul Parikh United States	6	244 0.8×	99 0.9×	146 1.5×	79 0.9×	15 0.2×	9	362
Longgang Cui China	7	297 0.9×	72 0.6×	159 1.6×	61 0.7×	65 0.8×	17	383

Countries citing papers authored by Brian Schillinger

Since Specialization

Citations

This map shows the geographic impact of Brian Schillinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Schillinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Schillinger more than expected).

Fields of papers citing papers by Brian Schillinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Schillinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Schillinger. The network helps show where Brian Schillinger may publish in the future.

Co-authorship network of co-authors of Brian Schillinger

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Schillinger. A scholar is included among the top collaborators of Brian Schillinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Schillinger. Brian Schillinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Ko, Andrew H., Alan P. Venook, Emily K. Bergsland, et al.. (2010). A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology. 66(6). 1051–1057. 66 indexed citations

Ko, Andrew H., Elizabeth Dito, Brian Schillinger, et al.. (2008). Excess Toxicity Associated with Docetaxel and Irinotecan in Patients with Metastatic, Gemcitabine-Refractory Pancreatic Cancer: Results of a Phase II Study. Cancer Investigation. 26(1). 47–52. 18 indexed citations

Ko, Andrew H., Elizabeth Dito, Brian Schillinger, et al.. (2008). A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?. Investigational New Drugs. 26(5). 463–471. 55 indexed citations

Ko, Andrew H., Elizabeth Dito, Brian Schillinger, et al.. (2008). A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC). Journal of Clinical Oncology. 26(15_suppl). 4516–4516. 11 indexed citations

Ko, Andrew H., Jeanne M. Quivey, Alan P. Venook, et al.. (2007). A Phase II Study of Fixed-Dose Rate Gemcitabine Plus Low-Dose Cisplatin Followed by Consolidative Chemoradiation for Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics. 68(3). 809–816. 80 indexed citations

Kavanagh, Brian D., Andrew H. Ko, Alan P. Venook, et al.. (2007). Vaccination of Metastatic Colorectal Cancer Patients With Matured Dendritic Cells Loaded With Multiple Major Histocompatibility Complex Class I Peptides. Journal of Immunotherapy. 30(7). 762–772. 83 indexed citations

Ko, Andrew H., Elizabeth Dito, Brian Schillinger, et al.. (2007). A phase II study of gemcitabine (GEM) given at fixed-dose rate (FDR) infusion, low-dose cisplatin (CDDP), and bevacizumab (BEV) for metastatic adenocarcinoma of the pancreas (PanCa): Update with completion of study accrual. Journal of Clinical Oncology. 25(18_suppl). 4548–4548. 2 indexed citations

Ko, Andrew H., Elizabeth Dito, Brian Schillinger, et al.. (2006). A phase II study of gemcitabine (GEM) given at fixed-dose rate (FDR) infusion, low-dose cisplatin (CDDP), and bevacizumab in metastatic pancreatic cancer (PanCa). Journal of Clinical Oncology. 24(18_suppl). 4041–4041. 2 indexed citations

Ko, Andrew H., Elizabeth Dito, Brian Schillinger, et al.. (2005). Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the Pancreas. Journal of Clinical Oncology. 24(3). 379–385. 54 indexed citations

10.

Ko, Andrew H., Elizabeth Dito, Brian Schillinger, et al.. (2004). A phase II study of fixed-dose rate (FDR) gemcitabine plus cisplatin for metastatic pancreatic adenocarcinoma (PanCa). Journal of Clinical Oncology. 22(14_suppl). 4107–4107. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact